Pharmigene Assets per Share

What does Pharmigene do? Pharmigene Inc, listed on the Taiwan Stock Exchange under ticker 7595.TWO with ISIN TW0007595B13, is a biotechnology company headquartered in Taipei City, Taiwan. The company went public on December 22, 2020. Pharmigene focuses on the development and commercialization of pharmaceutical genetic diagnostic products, operating within the healthcare sector. Its primary activities involve genomics science, specifically creating diagnostic kits, testing technologies, and comprehensive solutions for drug genomics research and development in precision medicine. The company offers a range of molecular diagnostic products, including the AutoEx16 automatic nucleic acid extractor, various gene test kits such as the Clopidogrel drug effectiveness test for CYP2C19*2&*3, and several test suites like SGE 1502, SGE 3101, and SGE 5701. Additionally, Pharmigene provides testing services encompassing drug genetic testing, functional medical testing, and personalized genetic testing. The firm primarily serves the Taiwan market, with some presence in other regions. Pharmigene's website is https://pharmigene.com.tw/. The company's operations are centered on advancing precision medicine through innovative diagnostic tools and services, aiming to support healthcare providers and researchers in tailoring medical treatments based on genetic profiles. Pharmigene is one of the most popular companies on Eulerpool.